Biotechnology News and Research

RSS

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Novel nanomaterials derived from cellulose have many promising industrial applications, are biobased and biodegradable, and can be produced at relatively low cost. Their potential toxicity--whether ingested, inhaled, on contact with the skin, or on exposure to cells within the body--is a topic of intense discussion, and the latest evidence and insights on cellulose nanocrystal toxicity are presented in a Review article in Industrial Biotechnology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

20 Feb 2015

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center.

19 Feb 2015

Researchers report development of first 3D tissue-engineered system

A team led by researchers at Tufts University School of Engineering and the University of Pavia has reported development of the first three-dimensional tissue system that reproduces the complex structure and physiology of human bone marrow and successfully generates functional human platelets.

19 Feb 2015

Novasep selected to commercially biomanufacture Celladon's Mydicar API

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®.

19 Feb 2015

Researchers assemble comprehensive map of human epigenome

Virtually every cell in the body carries an identical genome. But how is it possible that each of the body's 200 different types of specialized cells - in the heart, brain, bone, skin and elsewhere - develops from the same DNA instruction book?

19 Feb 2015

UCSD researchers make new attempt to develop malaria vaccine candidate

Researchers at University of California, San Diego School of Medicine used algae as a mini-factory to produce a malaria parasite protein. The algae-produced protein, paired with an immune-boosting cocktail suitable for use in humans, generated antibodies in mice that nearly eliminated mosquito infection by the malaria parasite.

19 Feb 2015

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the all new InspiraChamber Anti-Static Valved Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company InspiRX Inc.

19 Feb 2015

Dance Biopharm announces completion of $9.5 million convertible note and warrants financing

Dance Biopharm Inc., a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced the completion of a $9.5 million convertible note and warrants financing.

19 Feb 2015

PAREXEL International expands clinical trial site alliance network

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the continued expansion of its clinical trial site alliance network, an extensive network of investigator sites and Site Management Organizations (SMOs) that enables PAREXEL to quickly access and enroll patient populations for clients' clinical trials worldwide.

From Parexel 18 Feb 2015

First comprehensive maps and analyses of human epigenomes revealed

Two dozen scientific papers published online simultaneously on Feb. 18, 2015 present the first comprehensive maps and analyses of the epigenomes of a wide array of human cell and tissue types. Epigenomes are patterns of chemical annotations to the genome that determine whether, how, and when genes are activated.

18 Feb 2015

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Oncolytics Biotech Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer (IND 210). The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario.

18 Feb 2015

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that Israeli biotech investor Alex Rabinovich, its largest shareholder, increased his stake in the Company through his investment in InterCure, an XTL subsidiary, and recent purchases of XTL stock in the market.

17 Feb 2015

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for CF101 in the treatment of psoriasis.

17 Feb 2015

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

17 Feb 2015

Celon, Lupin sign definitive agreement to develop generic version of Advair Diskus

Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced today that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus®.

17 Feb 2015

BGRF announces publication of research into personalising nootropic drugs using in silico prediction methods

The Biogerontology Research Foundation (BGRF), a UK-based charity committed to the support of aging research to address the challenges of a rapidly aging population and to reduce the impact of disease on future generations, announces the publication of research into personalising nootropic drugs using in silico prediction methods.

17 Feb 2015

New laser technology shows promise for cancer treatment

Surgeons rely on 200-year-old technology when removing cancer--sight and touch--to determine how much to remove and what to leave alone. Laser technology pioneered at Florida Atlantic University has the promise to help a surgeon better determine if an area is cancer or healthy tissue. Moreover, when combined with laser treatment for cancer, this work lays the groundwork for laser robotic treatment of cancer.

16 Feb 2015

Study findings could help scientists better design silicon materials to improve chemotherapy drug delivery

A team of Israeli and American researchers have found that silicon nanomaterials used for the localized delivery of chemotherapy drugs behave differently in cancerous tumors than they do in healthy tissues. The findings could help scientists better design such materials to facilitate the controlled and targeted release of the chemotherapy drugs to tumors.

16 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Imperial College London to invest in new facility at Babraham Campus to support dynamic bioscience companies

Imperial College London is to invest in a new facility at the Babraham Research Campus in Cambridge to support spin-out and scale-up companies, and maximise the impact of research from universities.

From Abzena 13 Feb 2015

Biotechnology News and Research

Industrial Biotechnology presents insights on cellulose nanocrystal toxicity

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Researchers report development of first 3D tissue-engineered system

Novasep selected to commercially biomanufacture Celladon's Mydicar API

Researchers assemble comprehensive map of human epigenome

UCSD researchers make new attempt to develop malaria vaccine candidate

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Dance Biopharm announces completion of $9.5 million convertible note and warrants financing

PAREXEL International expands clinical trial site alliance network

First comprehensive maps and analyses of human epigenomes revealed

Oncolytics announces completion of patient enrollment in REOLYSIN Phase II colorectal cancer study

Biotech investor invests in InterCure to increase stake in XTL Biopharmaceuticals

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Celon, Lupin sign definitive agreement to develop generic version of Advair Diskus

BGRF announces publication of research into personalising nootropic drugs using in silico prediction methods

New laser technology shows promise for cancer treatment

Study findings could help scientists better design silicon materials to improve chemotherapy drug delivery

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Imperial College London to invest in new facility at Babraham Campus to support dynamic bioscience companies

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News